Xencor, Inc. (XNCR)
XNCR Stock Price Chart
Explore Xencor, Inc. interactive price chart. Choose custom timeframes to analyze XNCR price movements and trends.
XNCR Company Profile
Discover essential business fundamentals and corporate details for Xencor, Inc. (XNCR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Dec 2013
Employees
250.00
Website
https://www.xencor.comCEO
Bassil I. Dahiyat
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
XNCR Financial Timeline
Browse a chronological timeline of Xencor, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.72, while revenue estimate is $29.73M.
Earnings released on 6 Aug 2025
EPS came in at -$0.41 surpassing the estimated -$0.78 by +47.44%, while revenue for the quarter reached $43.61M , beating expectations by +78.94%.
Earnings released on 7 May 2025
EPS came in at -$0.66 falling short of the estimated -$0.63 by -4.76%, while revenue for the quarter reached $32.73M , beating expectations by +45.54%.
Earnings released on 27 Feb 2025
EPS came in at -$0.62 surpassing the estimated -$0.81 by +23.46%, while revenue for the quarter reached $70.02M , beating expectations by +313.33%.
Earnings released on 6 Nov 2024
EPS came in at -$0.71 surpassing the estimated -$0.98 by +27.55%, while revenue for the quarter reached $10.71M , missing expectations by -35.56%.
Earnings released on 5 Aug 2024
EPS came in at -$1.07 falling short of the estimated -$0.85 by -25.88%, while revenue for the quarter reached $16.96M , beating expectations by +7.14%.
Earnings released on 9 May 2024
EPS came in at -$1.11 falling short of the estimated -$0.76 by -46.05%, while revenue for the quarter reached $12.81M , missing expectations by -48.76%.
Earnings released on 27 Feb 2024
EPS came in at -$0.31 falling short of the estimated $0.36 by -186.11%, while revenue for the quarter reached $44.69M , missing expectations by -39.48%.
Earnings released on 7 Nov 2023
EPS came in at -$0.40 surpassing the estimated -$0.77 by +48.05%, while revenue for the quarter reached $59.16M , beating expectations by +101.79%.
Earnings released on 3 Aug 2023
EPS came in at -$0.37 surpassing the estimated -$0.91 by +59.34%, while revenue for the quarter reached $45.52M , beating expectations by +57.03%.
Earnings released on 8 May 2023
EPS came in at -$1.02 falling short of the estimated -$0.75 by -36.00%, while revenue for the quarter reached $18.96M , missing expectations by -32.21%.
Earnings released on 23 Feb 2023
EPS came in at -$0.20 surpassing the estimated -$0.83 by +75.90%, while revenue for the quarter reached $21.61M , beating expectations by +7.68%.
Earnings released on 7 Nov 2022
EPS came in at -$0.55 surpassing the estimated -$0.77 by +28.57%, while revenue for the quarter reached $27.30M , beating expectations by +29.68%.
Earnings released on 3 Aug 2022
EPS came in at -$0.57 falling short of the estimated -$0.45 by -26.67%, while revenue for the quarter reached $30.18M , missing expectations by -11.28%.
Earnings released on 5 May 2022
EPS came in at $0.39 surpassing the estimated -$0.61 by +163.93%, while revenue for the quarter reached $85.50M , beating expectations by +227.04%.
Earnings released on 23 Feb 2022
EPS came in at $1.21 surpassing the estimated -$0.10 by +1.31K%, while revenue for the quarter reached $154.02M , beating expectations by +101.88%.
Earnings released on 8 Nov 2021
EPS came in at -$0.69 surpassing the estimated -$0.75 by +8.00%, while revenue for the quarter reached $19.68M , missing expectations by -7.76%.
Earnings released on 4 Aug 2021
EPS came in at $0.87 surpassing the estimated -$0.56 by +255.36%, while revenue for the quarter reached $67.45M , beating expectations by +243.94%.
Earnings released on 5 May 2021
EPS came in at -$0.04 surpassing the estimated -$0.77 by +94.81%, while revenue for the quarter reached $33.97M , beating expectations by +115.10%.
Earnings released on 23 Feb 2021
EPS came in at -$0.24 surpassing the estimated -$0.54 by +55.56%, while revenue for the quarter reached $41.85M , beating expectations by +42.07%.
Earnings released on 5 Nov 2020
EPS came in at -$0.22 matching the estimated -$0.22, while revenue for the quarter reached $35.37M , missing expectations by -4.17%.
XNCR Stock Performance
Access detailed XNCR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.